Merck’s adjusted revenue guidance shows product mix matters during COVID-19

Merck’s heavy reliance on hospital-administered products, vaccines and animal health has left it more exposed than its pharma peers to the commercial impacts of the COVID-19 pandemic.

The company cut its 2020 revenue guidance by $2.5 billion with expectations now coming in at $46.1-$48.1 billion, citing a 70% decline in patient well-visits and elective surgeries, plus smaller drops in urgent surgeries and even new oncology patient visits.

On its 1Q20 earnings call, COO and EVP Frank Clyburn

Read the full 775 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE